How Patient Age, Vector Dose, and Immune Response Figure in Gene Therapy for Duchenne Muscular Dystrophy
August 8, 2023 | Terry Sharrer
“Based on the finding, the researchers [Sarepta Therapeutics] identified a need for more data on the characteristics that may predispose people to severe Sarepta Therapeutics innate immune reactions and concluded “dose determination will remain a challenge for custom-designed AAV-mediated therapies, as by definition the precise therapeutic dose will not have been established.” MORE
Image Credit: Factor Bioscience